ALKBH7

Across TCGA pan-cancer cohorts, ALKBH7 mass-spec protein is linked to patient survival in 4 of 34 cancer types, making it a survival-associated ALKBH7 data layer compared with 20 for mass-spec protein.

The strongest signal is observed in lung adenocarcinoma (LUAD), where higher ALKBH7 mass-spec protein is associated with better overall survival. In most high-consensus cancer types, elevated ALKBH7 expression acts as an unfavorable survival marker, although some lineages such as LUAD and CCRCC show a favorable association.

LUAD, CCRCC, and LSCC are the cancer types where ALKBH7 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
LUAD	OS	Median	All	1.000	0.609	.002	23	view →
CCRCC	DFS	Tertile	All	0.982	0.436	.010	21	view →
LSCC	DFS	Tertile	II,III,IV	0.937	0.669	.006	9	view →
PDAC	OS	Quartile	All	0.938	0.587	.048	1	view →

Pink = unfavorable, green = favorable. Showing the 4 strongest of 4 lineages.

ALKBH7–LUAD (OS)

Open the LUAD breakdown →